Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 August 2005, Vol. 106, No. 4, pp. 1495-1500.
Prepublished online as a Blood First Edition Paper on May 5, 2005; DOI 10.1182/blood-2004-11-4557.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-11-4557v1
106/4/1495    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cahn, J.-Y.
Right arrow Articles by Socie, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cahn, J.-Y.
Right arrow Articles by Socie, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted December 1, 2004
Accepted April 15, 2005

Prospective evaluation of two acute graft-versus-host (GVHD) grading systems: A joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI) and International Bone Marrow Transplant Registry (IBMTR) prospective study

Jean-Yves Cahn*, John P Klein, Stephanie J Lee, Noel Milpied, Didier Blaise, Joseph H Antin, Veronique Leblond, Norbert Ifrah, Jean- Pierre Jouet, Fausto Loberiza, Olle Ringden, A J Barrett, Mary M Horowitz, and Gerard Socie

Hematology Department, Centre Hospitalo-Universitaire, Grenoble, France
International Bone Marrow Transplant Registry, Medical College of Wisconsin, Milwaukee, WI, USA
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Hematology Department, Centre Hospitalo-Universitaire, Nantes, France
Hematology Department, Institut Paoli-Calmettes, Marseille, France
Hematology Department, Hopital La Pitie Salpetriere, Paris, France
Hematology Department, Centre Hospitalo-Universitaire Angers, Angers, France
Hematology Department, Centre Hospitalo-Universitaire Lille, Lille, France
Huddinge University Hospital, Stockholm, Sweden
National Institute of Health, Bethesda, MD, USA
Hopital Saint-Louis, Paris, France

* Corresponding author; email: JYCahn{at}chu-grenoble.fr.

The most commonly used grading system for acute graft-versus-host disease (aGVHD) was introduced thirty years ago by Glucksberg; a revised system was developed by the International Bone Marrow Transplant Registry (IBMTR) in 1997. To prospectively compare the two classifications and to evaluate the effect of duration and severity of aGVHD on survival, we conducted a multicenter study of 607 patients receiving T cell replete allografts, scored weekly for aGVHD in 18 transplant centers. Sixty-nine percent of donors were HLA-identical siblings and 28%, unrelated donors. The conditioning regimen included total body irradiation in 442 (73%) patients. The two classifications performed similarly in explaining variability in survival by aGVHD grade though the Glucksberg classification predicted early survival better. There was less physician bias or error in assigning grades with the IBMTR scoring system. With either system, only maximum observed grade had prognostic significance for survival; neither time of onset nor progression from an initially lower grade of aGVHD was associated with survival once maximum grade was considered. Regardless of scoring system, aGVHD severity accounted for only a small percentage of observed variation in survival. Validity of these results in populations receiving peripheral blood transplants or non-myeloablative conditioning regimens remains to be tested.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Sci Transl MedHome page
S. Paczesny, T. M. Braun, J. E. Levine, J. Hogan, J. Crawford, B. Coffing, S. Olsen, S. W. Choi, H. Wang, V. Faca, et al.
Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin
Science Translational Medicine, January 6, 2010; 2(13): 13ra2 - 13ra2.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Pavletic
aGVHDAI: escape from the silo
Blood, July 15, 2006; 108(2): 412 - 413.
[Full Text] [PDF]


Home page
BloodHome page
W. M. Leisenring, P. J. Martin, E. W. Petersdorf, A. E. Regan, N. Aboulhosn, J. M. Stern, S. N. Aker, R. C. Salazar, and G. B. McDonald
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens
Blood, July 15, 2006; 108(2): 749 - 755.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020